Clazakizumab

Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Antibody, MAB, Asia, Allergy, Chronic inflammatory demyelinating polyneuropathy, Acquisition, Bacteria, Saliva, IGG, Clazakizumab, Antigen, Virus, Myasthenia gravis, Blood, Laboratory, COVID-19, Immunoglobulin G, Hypogammaglobulinemia, Research, Risk, Purpura, IGE, CSL Behring, Organization, IGD, III, Lymph, Infection, CIDP, ITP, IGA, IGM, B cell, Vaccine, Blood product

The "Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • The immunoglobulins market consists of sales of immunoglobulins by entities (organizations, sole traders, and partnerships) that are used to measure the level of types of antibodies in the blood.
  • The launch of new offices and laboratories to boost research and development activities is shaping the immunoglobulins market.
  • Thus, the increasing geriatric population is expected to increase the demand for the immunoglobulins market during the forecast period.

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Retrieved on: 
Tuesday, March 30, 2021
Medical specialties, Monoclonal antibodies, Clinical medicine, Medicine, Interleukin-6 receptor, Foralumab, Anti-CD3 monoclonal antibody, Monoclonal antibody therapy, Clazakizumab

A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.

Key Points: 
  • A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.
  • Tiziana now plans a phase 2 randomized, placebo-controlled trial in Brazil for moderate to severe hospitalized Covid-19 patients to test the drug in a more compromised group of patients.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Retrieved on: 
Monday, November 9, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Organ systems, Autoimmune diseases, Rheumatology, Monoclonal antibodies, Psoriasis, Psoriatic arthritis, Bristol Myers Squibb, Arthritis, Clazakizumab, Infliximab, the Phase 2 Deucravacitinib Psoriatic Arthritis Trial, Psoriatic Arthritis, Deucravacitinib, Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) today announced results from an ongoing Phase 2 study evaluating the safety and efficacy of deucravacitinib (BMS-986165) 6 mg or 12 mg once daily, compared with placebo in adults with active psoriatic arthritis.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced results from an ongoing Phase 2 study evaluating the safety and efficacy of deucravacitinib (BMS-986165) 6 mg or 12 mg once daily, compared with placebo in adults with active psoriatic arthritis.
  • In this trial, deucravacitinib was well-tolerated and the safety profile was similar to that observed in the previously reported Phase 2 psoriasis trial.
  • Deucravacitinib is being studied in a wide spectrum of immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia

Retrieved on: 
Friday, September 18, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Health, Articles, Clinical research, Design of experiments, Pharmaceutical industry, Immunosuppressants, Orphan drugs, Tocilizumab, Clinical trial, Coronavirus disease, Placebo-controlled study, Clazakizumab, the EMPACTA Trial, the REMDACTA Trial, Actemra, Genentech

The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.

Key Points: 
  • The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.
  • Actemra is currently being investigated as a potential treatment for COVID-19 associated pneumonia, including in combination with an anti-viral in the Phase III REMDACTA clinical trial.
  • Results from the Phase III COVACTA trial in patients with severe COVID-19 associated pneumonia were released in July.
  • EMPACTA (Evaluating Minority Patients with Actemra) is a Phase III, randomized, double-blind, placebo-controlled multicenter study (EMPACTA, NCT04372186) to evaluate the efficacy and safety of Actemra in the treatment of hospitalized COVID-19 associated pneumonia among patients that are often underrepresented in clinical trials.

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

Retrieved on: 
Thursday, September 17, 2020
Medical specialties, Clinical medicine, Monoclonal antibodies, Medicine, Foralumab, Interleukin-6 receptor, Interleukin 6, Dexamethasone, Anti-CD3 monoclonal antibody, Monoclonal antibody therapy, Clazakizumab

Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.

Key Points: 
  • Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19

Retrieved on: 
Thursday, July 30, 2020
Health, Clinical research, Medical research, Medicine, Design of experiments, Clinical trial, Placebo-controlled study, Placebo, Tcelna, Clazakizumab

We quickly launched a Phase 2 study in the U.S. and are now expanding the program globally with a Phase 2/3 study to allow us to collect a broad and rigorous data set in a short amount of time.

Key Points: 
  • We quickly launched a Phase 2 study in the U.S. and are now expanding the program globally with a Phase 2/3 study to allow us to collect a broad and rigorous data set in a short amount of time.
  • The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study ( NCT04467840 ) is set to enroll up to 270 patients in up to 40 clinical sites across European, Latin American and other countries.
  • The primary endpoint of the study is to evaluate the proportion of patients requiring intubation and mechanical ventilation by Day 14.
  • Enrollment is also ongoing for a randomized, double-blind, placebo-controlled Phase 2 clinical study with opaganib in the U.S. ( NCT04414618 ).

Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia

Retrieved on: 
Wednesday, July 29, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Health, Clinical research, Medical research, Articles, Design of experiments, Drug discovery, Pharmaceutical industry, Placebo-controlled study, Placebo, Clinical trial, Coronavirus disease, Clazakizumab, the COVACTA Trial, Actemra, Genentech

COVACTA evaluated the safety and efficacy of intravenous Actemra added to standard-of-care treatment and compared to treatment with placebo plus standard of care.

Key Points: 
  • COVACTA evaluated the safety and efficacy of intravenous Actemra added to standard-of-care treatment and compared to treatment with placebo plus standard of care.
  • The COVACTA trial is the first global, randomized, double-blind, placebo-controlled Phase III study to investigate Actemra in adult patients hospitalized with severe COVID-19 associated pneumonia, with study locations in the United States, Canada and Europe.
  • Time to hospital discharge or ready to discharge was shorter in patients treated with Actemra than those treated with placebo.
  • In addition to COVACTA, Genentech has initiated several studies to further investigate Actemra as a potential treatment for patients with COVID-19 associated pneumonia, including two Phase III clinical trials, REMDACTA and EMPACTA, as well as the Phase II MARIPOSA trial.

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

Retrieved on: 
Tuesday, June 30, 2020
Pyrimidines, Organofluorides, Antibodies, Bristol-Myers Squibb, Clazakizumab, Chemistry, Palifermin

We are extremely grateful to all of our investigators and study patients, particularly given that this study cohort was completed amidst the COVID-19 pandemic."

Key Points: 
  • We are extremely grateful to all of our investigators and study patients, particularly given that this study cohort was completed amidst the COVID-19 pandemic."
  • The BALANCED study is an ongoing randomized, double-blind, placebo-controlled study in NASH patients.
  • The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult patients with NASH.
  • Efruxifermin (EFX), formerly known as AKR-001, is Akero's lead product candidate for NASH, currently being evaluated in the ongoing Phase 2a BALANCED study.

First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

Retrieved on: 
Tuesday, April 28, 2020
Monoclonal antibodies, Drugs, Medical research, Medicine, Amatuximab, Clazakizumab

The Phase II trial is supported by an exploratory translational study, EXPLORE COVID-19 , which suggests that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR pathway.

Key Points: 
  • The Phase II trial is supported by an exploratory translational study, EXPLORE COVID-19 , which suggests that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR pathway.
  • Avdoralimab is a monoclonal antibody that blocks C5aR and has the potential to reduce the inflammatory response in the lungs, said Pr.
  • In this randomized trial, we hope to demonstrate that the use of avdoralimab helps improve the prognosis of COVID-19 patients with severe pneumonia.
  • FORCE is a multi-center, randomized, double-blind, placebo-controlled Phase II trial evaluating avdoralimab in COVID-19 patients with severe pneumonia.

Genentech Initiates Phase III Clinical Trial of Actemra in Hospitalized Patients With Severe COVID-19 Pneumonia

Retrieved on: 
Thursday, March 19, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Health, Clinical research, Design of experiments, Articles, Medical research, Genentech, Clinical trial, Placebo-controlled study, Clazakizumab, the Clinical Trial, Actemra, Genentech

To date, there are several independent clinical trials exploring the efficacy and safety of Actemra for the treatment of patients with COVID-19 pneumonia.

Key Points: 
  • To date, there are several independent clinical trials exploring the efficacy and safety of Actemra for the treatment of patients with COVID-19 pneumonia.
  • Genentech is initiating a randomized, double-blind, placebo-controlled Phase III study (COVACTA) to evaluate the safety and efficacy of intravenous Actemra added to standard of care in adult patients hospitalized with severe COVID-19 pneumonia compared to placebo plus standard of care.
  • The extensive Actemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries.
  • The Actemra RA subcutaneous clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in 33 countries.